Patients’ characteristics at the time of sampling
| Demographics of HDs (n = 49) . | ||||
|---|---|---|---|---|
| Sex (M/F), n (%): 24 (49%)/25(51%) | ||||
| Median age, y (IQR): 69 (60-85) | ||||
| Clinical features of patients with CLL | Total (n = 74) | Untreated (n = 27) | Chemotherapy (n = 17) | Ibrutinib (n = 30) |
| Sex (M/F), n (%) | 46 (62%)/28 (39%) | 10 (37%)/17(63%) | 9 (53%)/8 (47%) | 9 (30%)/21 (70%) |
| Median age, y (IQR) | 69.5 (50-86) | 70 (50-86) | 68 (57-81) | 71(63-86) |
| Rai stage at onset, n (%) | ||||
| 0 | 17 (23%) | 14 (52%) | 2 (12%) | 1 (3%) |
| I | 31 (42%) | 12 (44%) | 6 (35%) | 13 (43%) |
| II | 13 (17%) | 0 (0%) | 5 (29%) | 8 (27%) |
| III | 8 (11%) | 1 (4%) | 2 (12%) | 5 (17%) |
| IV | 5 (7%) | 0 (0%) | 2 (12%) | 3 (10%) |
| Binet stage at onset, n (%) | ||||
| A | 30 (40%) | 22 (81%) | 3 (18%) | 5 (16%) |
| B | 31 (43%) | 4 (15%) | 10 (59%) | 17 (57%) |
| C | 13 (17%) | 1 (4%) | 4 (23%) | 8 (27%) |
| Rai stage at sampling, n (%) | ||||
| 0 | 41 (55%) | 13 (48%) | 10 (58%) | 18 (60%) |
| I | 25 (34%) | 12 (44%) | 3 (18%) | 10 (34%) |
| II | 3 (4%) | 1 (4%) | 2 (12%) | 0 (0%) |
| III | 3 (4%) | 1 (4%) | 1 (6%) | 1 (3%) |
| IV | 2 (3%) | 0 (0%) | 1 (6%) | 1 (3%) |
| Binet stage at sampling, n (%) | ||||
| A | 53 (71%) | 22 (81%) | 13 (76%) | 18 (60%) |
| B | 16 (22%) | 4 (15%) | 2 (12%) | 10 (33%) |
| C | 5 (7%) | 1 (4%) | 2 (12%) | 2 (7%) |
| Lymphocyte count at sampling, × 109/L, median (IQR) | 7 700 (2 075-20 585) | 18 140 (9 050-32 730) | 3 450 (1 585-20 420) | 4 650 (1 697-10 497) |
| % CLL cells, median (IQR) | 35 (12-67) | 64 (29-75) | 20 (5-52) | 30 (11-51) |
| Lines of therapy, n | ||||
| 1 | 24 | 0 | 16 | 12 |
| 2 | 7 | 0 | 1 | 6 |
| 3 | 8 | 0 | 0 | 8 |
| 4 | 4 | 0 | 0 | 4 |
| Response to therapy, n | ||||
| Complete remission | 29 | 0 | 12 | 17 |
| Partial remission | 18 | 0 | 5 | 13 |
| CNAs, n (%) | ||||
| Favorable | 52 (70%) | 25 (93%) | 10 (59%) | 17 (57%) |
| Intermediate | 15 (20%) | 2 (7%) | 6 (35%) | 7 (23%) |
| Unfavorable | 7 (10%) | 0 (0%) | 1 (6%) | 6 (20%) |
| IGHV mutational status, n (%) | ||||
| UM | 42 (57%) | 9 (33%) | 9 (53%) | 24 (80%) |
| Mut | 32 (43%) | 18 (67%) | 8 (47%) | 6 (20%) |
| CD38, n (%) | ||||
| Pos | 24 (33%) | 5 (19%) | 7 (41%) | 12 (40%) |
| Neg | 50 (67%) | 22 (81%) | 10 (59%) | 18 (60%) |
| CD49d, n (%) | ||||
| Pos | 37 (50%) | 9 (33%) | 10(59%) | 18 (60%) |
| Neg | 37 (50%) | 18 (67%) | 7 (41%) | 12 (40%) |
| ZAP70, n (%) | ||||
| Pos | 22 (36%) | 7 (26%) | 7 (41%) | 8 (27%) |
| Neg | 40 (64%) | 13 (48%) | 9 (53%) | 18 (60%) |
| NOTCH1, n (%) | ||||
| UM | 61 (82%) | 24 (89%) | 15 (88%) | 22 (73%) |
| Mut | 13 (18%) | 3 (11%) | 2 (12%) | 8 (27%) |
| TP53, n (%) | ||||
| UM | 63 (85%) | 27 (100%) | 15 (88%) | 21 (70%) |
| Mut | 11 (15%) | 0 (0%) | 2 (12%) | 9 (30%) |
| Demographics of HDs (n = 49) . | ||||
|---|---|---|---|---|
| Sex (M/F), n (%): 24 (49%)/25(51%) | ||||
| Median age, y (IQR): 69 (60-85) | ||||
| Clinical features of patients with CLL | Total (n = 74) | Untreated (n = 27) | Chemotherapy (n = 17) | Ibrutinib (n = 30) |
| Sex (M/F), n (%) | 46 (62%)/28 (39%) | 10 (37%)/17(63%) | 9 (53%)/8 (47%) | 9 (30%)/21 (70%) |
| Median age, y (IQR) | 69.5 (50-86) | 70 (50-86) | 68 (57-81) | 71(63-86) |
| Rai stage at onset, n (%) | ||||
| 0 | 17 (23%) | 14 (52%) | 2 (12%) | 1 (3%) |
| I | 31 (42%) | 12 (44%) | 6 (35%) | 13 (43%) |
| II | 13 (17%) | 0 (0%) | 5 (29%) | 8 (27%) |
| III | 8 (11%) | 1 (4%) | 2 (12%) | 5 (17%) |
| IV | 5 (7%) | 0 (0%) | 2 (12%) | 3 (10%) |
| Binet stage at onset, n (%) | ||||
| A | 30 (40%) | 22 (81%) | 3 (18%) | 5 (16%) |
| B | 31 (43%) | 4 (15%) | 10 (59%) | 17 (57%) |
| C | 13 (17%) | 1 (4%) | 4 (23%) | 8 (27%) |
| Rai stage at sampling, n (%) | ||||
| 0 | 41 (55%) | 13 (48%) | 10 (58%) | 18 (60%) |
| I | 25 (34%) | 12 (44%) | 3 (18%) | 10 (34%) |
| II | 3 (4%) | 1 (4%) | 2 (12%) | 0 (0%) |
| III | 3 (4%) | 1 (4%) | 1 (6%) | 1 (3%) |
| IV | 2 (3%) | 0 (0%) | 1 (6%) | 1 (3%) |
| Binet stage at sampling, n (%) | ||||
| A | 53 (71%) | 22 (81%) | 13 (76%) | 18 (60%) |
| B | 16 (22%) | 4 (15%) | 2 (12%) | 10 (33%) |
| C | 5 (7%) | 1 (4%) | 2 (12%) | 2 (7%) |
| Lymphocyte count at sampling, × 109/L, median (IQR) | 7 700 (2 075-20 585) | 18 140 (9 050-32 730) | 3 450 (1 585-20 420) | 4 650 (1 697-10 497) |
| % CLL cells, median (IQR) | 35 (12-67) | 64 (29-75) | 20 (5-52) | 30 (11-51) |
| Lines of therapy, n | ||||
| 1 | 24 | 0 | 16 | 12 |
| 2 | 7 | 0 | 1 | 6 |
| 3 | 8 | 0 | 0 | 8 |
| 4 | 4 | 0 | 0 | 4 |
| Response to therapy, n | ||||
| Complete remission | 29 | 0 | 12 | 17 |
| Partial remission | 18 | 0 | 5 | 13 |
| CNAs, n (%) | ||||
| Favorable | 52 (70%) | 25 (93%) | 10 (59%) | 17 (57%) |
| Intermediate | 15 (20%) | 2 (7%) | 6 (35%) | 7 (23%) |
| Unfavorable | 7 (10%) | 0 (0%) | 1 (6%) | 6 (20%) |
| IGHV mutational status, n (%) | ||||
| UM | 42 (57%) | 9 (33%) | 9 (53%) | 24 (80%) |
| Mut | 32 (43%) | 18 (67%) | 8 (47%) | 6 (20%) |
| CD38, n (%) | ||||
| Pos | 24 (33%) | 5 (19%) | 7 (41%) | 12 (40%) |
| Neg | 50 (67%) | 22 (81%) | 10 (59%) | 18 (60%) |
| CD49d, n (%) | ||||
| Pos | 37 (50%) | 9 (33%) | 10(59%) | 18 (60%) |
| Neg | 37 (50%) | 18 (67%) | 7 (41%) | 12 (40%) |
| ZAP70, n (%) | ||||
| Pos | 22 (36%) | 7 (26%) | 7 (41%) | 8 (27%) |
| Neg | 40 (64%) | 13 (48%) | 9 (53%) | 18 (60%) |
| NOTCH1, n (%) | ||||
| UM | 61 (82%) | 24 (89%) | 15 (88%) | 22 (73%) |
| Mut | 13 (18%) | 3 (11%) | 2 (12%) | 8 (27%) |
| TP53, n (%) | ||||
| UM | 63 (85%) | 27 (100%) | 15 (88%) | 21 (70%) |
| Mut | 11 (15%) | 0 (0%) | 2 (12%) | 9 (30%) |
CNAs, copy number alterations; F, female; M, male; IQR, interquartile range; Mut, mutated; Neg, negative; Pos, positive; UM, unmutated.